Further, a mouse study of AD found that treatment with a dual GLP-1R/GIPR agonist significantly reduced reactive astrogliosis relative to treatment with the single GLP-1R agonist liraglutide [80]. This evidence concerns the gene GIPR and Alzheimer disease.